Trial Profile
A Phase 2 Study of Pembrolizumab in Combination With Pelareorep in Patients With Advanced Pancreatic Adenocarcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Pelareorep (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Proof of concept; Therapeutic Use
- 13 Jul 2023 Results assessing if pelareorep and pembrolizumab has efficacy by inducing anti-tumour immunological changes published in the British Journal of Cancer
- 30 Aug 2021 Status changed from active, no longer recruiting to discontinued due to The total accrual goal of 34 patients was not met. Stage 1 of the study did not meet the interim analysis criteria to move onto Stage 2 of the Simon 2 stage design. .
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology